arrow
M

Marco Trevisan

janssen pharmaceuticals
H指数:27
被引数:2,362

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes

BRCA1/2和同源重组修复在高、低容量转移性激素敏感型前列腺癌中的改变: 患病率及其对预后的影响

2025-06-020
OAAI
Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)

FANCA、ATM、CDK12改变对转移性去势抵抗性前列腺癌(mCRPC)生存的影响

2024-09-010
PRE
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
2024-07-030
OAAI
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes

伴或不伴同源重组修复基因体细胞或种系改变的转移性去势抵抗性前列腺癌患者的治疗模式和结果

2024-05-019
OA
Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection
2021-06-1118
OA